Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study
Francesca Sofia Di Lisa, Enzo Veltri(Ospedale Santa Maria Goretti), Lorenzo Gianni, Salvatore Artale(Ospedale San Carlo), Rosalba Torrisi(IRCCS Humanitas Research Hospital), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Antonino Grassadonia(University of Chieti-Pescara), Rossana Berardi(Marche Polytechnic University), Andrea Botticelli(Policlinico Umberto I), Katia Cannita(Ospedale San Giuseppe), Nicola Tinari(University of Chieti-Pescara), Fable Zustovich, Ida Paris(Agostino Gemelli University Polyclinic), Andrea Michelotti(Ospedale Santa Chiara), Nicla La Verde(ASST Fatebenefratelli Sacco), Simone Scagnoli(Sapienza University of Rome), L. Rinaldi(Istituto Tumori Bari), Teresa Gamucci, Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Lorenzo Livi(European Society for Sexual Medicine), Emanuela Risi(Unknown), Marco Mitidieri, Margherita Muratore(Agostino Gemelli University Polyclinic), Eriseld Krasniqi(National Cancer Institute), Giuseppe Tonini(Campus Bio Medico University Hospital), Lorenza Landi(Tumori Foundation), Giuliana D’Auria(Ospedale di Belcolle), Maddalena Barba(National Cancer Institute), Simonetta Chiara Stani(Ospedale di Santo Spirito), Valentina Sini(Ospedale di Santo Spirito), Giuseppina Sarobba(Associazione Istituzione Libera Università Nuorese), Beatrice Fratini(Azienda Ospedaliera Universitaria Pisana), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Francesco Giotta(Istituto Tumori Bari), Valeria Gaspari(Azienda USL di Bologna), Mirco Pistelli(Ospedali Riuniti Umberto I), Rosa Saltarelli, Alessandra Cassano, Matteo Vergati(National Institutes of Health), Fulvio Borella(Ospedale Sant'Anna), Anna Cariello(Azienda Unità Sanitaria Locale Della Romagna), Antonella Ferro(Ospedale Santa Chiara), Daniele Santini(Policlinico Umberto I), Vito Lorusso, Icro Meattini(Azienda Ospedaliero-Universitaria Careggi), Elisa Picardo(Ospedale Sant'Anna), Federico Cappuzzo(Ospedale di Livorno), Jennifer Foglietta, Laura Pizzuti
Cited by 9
Related Papers
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
|JNCI Journal of the National Cancer Institute|2005|1.6k